Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMOkids: PK of Temozolomide Oral Suspension (KIMOZO) in Pediatric Cancer
NCT04610736Phase 1Completed
- Sponsor
- ORPHELIA Pharma
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in pediatric cancer, sponsored by ORPHELIA Pharma. Primary endpoints: Area Under the Curve over 24 hours at Day 1, Maximum Plasma Concentration at Day 1 and 1 more. Started Mar 2021; status: completed.
02
Drugs
temozolomide
03
Conditions
pediatric cancer
Beyond the preview
Go deeper on NCT04610736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610736.